Q-omics provides the consensus-scored RPL23AP26 profile across patient tissues and cancer cell-line models. RPL23AP26 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL23AP26 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RPL23AP26 RNA expression shows 6,514 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where RPL23AP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP26 survival associations across molecular data types. RPL23AP26 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP26 RNA expression–survival associations across cancer types. High RPL23AP26 expression shows unfavorable associations in ACC, KICH, PAAD, STAD and CESC, but favorable associations in COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL23AP26 RNA expression.
This table summarizes RPL23AP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP26 shows higher tumor expression in BRCA. The BRCA box plot shows higher RPL23AP26 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .025).
This table shows molecular features associated with RPL23AP26 in patient tissues and cancer cell lines. In patient samples, RPL23AP26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
